利妥昔单抗辅助CHOP方案治疗B细胞型非霍奇金淋巴瘤的可行性分析  

Feasibility analysis of Rituximab assisted CHOP regimen in the treatment of B cell non Hodgkin lymphoma

作　　者：唐玫琴[1] 涂传清[2] 田发青[1] 李举亨[1] 蒋剑 成小慧 TANG Mei-qin;TU Chuan-qing;TIAN Fa-qing(Department of Hematology,Shenzhen Longgang District People’s Hospital,Shenzhen 518172,China)

机构地区：[1]深圳市龙岗区人民医院血液内科,518172 [2]深圳市宝安区人民医院血液内科,518101

出　　处：《中国现代药物应用》2018年第15期99-100,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨利妥昔单抗辅助CHOP方案治疗B细胞型非霍奇金淋巴瘤的临床应用效果。方法 60例B细胞型非霍奇金淋巴瘤患者,按照随机数字法分为对照组和研究组,每组30例。对照组予以CHOP方案治疗,研究组在对照组基础上加以利妥昔单抗辅助治疗。比较两组患者临床疗效及不良反应发生情况。结果研究组临床总有效率90.00%显著高于对照组的66.67%,差异具有统计学意义(P<0.05)。两组患者的各项不良反应发生率比较差异无统计学意义(P>0.05)。结论利妥昔单抗辅助CHOP方案治疗B细胞型非霍奇金淋巴瘤疗效确切,不增加不良反应发生率,值得在临床上推广使用。Objective To investigate the clinical application effect of Rituximab assisted CHOP regimen in the treatment of B cell non Hodgkin lymphoma.Methods A total of 60 patients with B cell non Hodgkin lymphoma were divided into control group and research group according to the random number table method,30 cases in each group.The control group was given CHOP regimen for treatment,the research group was given Rituximab assisted therapy on the basis of control group.The clinical effect and occurrence of adverse reactions between the two groups were compared.Results The total effective rate of the research group was 90.00%,which was significantly higher than 66.67%in the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions(P>0.05).Conclusion Rituximab assisted CHOP regimen in the treatment of B cell non Hodgkin lymphoma is effective.It does not increase the incidence of adverse reactions,and is worthy of clinical application.

关 键 词：B细胞 非霍奇金淋巴瘤 利妥昔单抗 CHOP方案 

分 类 号：R733.1[医药卫生—肿瘤]